South Korea has become a significant player in the global pharmaceutical industry and drug development space, fueled by its advanced healthcare system, growing pharmaceutical sector, strong research infrastructure, and government-backed initiatives to support innovation. The country has been increasingly focusing on innovation and cutting-edge technologies, such as CGTs, as well as development of advanced therapies such as ADCs, mRNA-based treatments, and CAR-T therapies. As a result, South Korea is establishing itself as a growing hub for clinical trials and drug development, attracting global attention and investment.
In this report, The analyst explores the key metrics shaping South Korea’s drug development landscape, including approved and pipeline drugs, the clinical trials landscape, as well as deal-making trends, to assess its impact on the global pharmaceutical industry.
In this report, The analyst explores the key metrics shaping South Korea’s drug development landscape, including approved and pipeline drugs, the clinical trials landscape, as well as deal-making trends, to assess its impact on the global pharmaceutical industry.
Key Findings of the report include:
- South Korea’s drug development is growing, focusing on early R&D and CGTs.
- South Korea is advancing therapies like ADCs, mRNA, and CAR-T.
- The rise in drug approvals in recent years highlights South Korea’s strong regulatory support.
- South Korea’s pharma deals have slowed in recent years, but strategic alliances remain key.
- Phase I clinical trials have become the focus in South Korea, representing the largest category.
Scope
Study objectives
- To analyze South Korea’s drug development activities, including the most promising agents
- To explore the growth of CAR-T cell and ADC therapies in this market
- To examine the role of South Korea’s regulatory environment in accelerating the approval of innovative therapies
- To assess the growth in clinical trials conducted in South Korea
- To analyze deal-making activity trends
Report design
- The data presented in this report is taken from the analyst’s drug, clinical trials, and deals databases
- The sources were accessed and data was derived in February 2025
Reasons to Buy
- Gain insights into South Korea’s rapidly evolving drug development landscape, including key innovative therapies.
- Understand the growth trajectory and market potential of CAR-T cell and ADC therapies in South Korea.
- Explore the impact of South Korea’s regulatory reforms on the accelerated approval.
- Stay informed on the increasing number of clinical trials conducted in South Korea.
- Identify emerging trends in deal-making activities and partnership opportunities.
Table of Contents
1 Executive Summary
2 Introduction
3. Drug Development Trends
4 Summary of Key Findings
5 Appendix
6 About the Authors
7 Contact the Publisher
